HSV-2 vaccine: Current state and insights into development of a vaccine that targets genital mucosal protection

Microbial Pathogenesis

Volumn 58, Issue , 2013, Pages 45-54

  Roth, Kristy ^a   Ferreira, Victor H ^a   Kaushic, Charu ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Genital tract; HSV vaccine trials; HSV 2; Mucosal adjuvants; Mucosal immunity; Sex hormones

Indexed keywords

BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GEN 003; HERPES SIMPLEX VACCINE; HERPES SIMPLEX VIRUS 2 DELETED GENE GH VACCINE; HERPES SIMPLEX VIRUS 2 DELETED GENE UL39 VACCINE; HERPES SIMPLEX VIRUS 2 DELETED GENE UL5 AND UL29 VACCINE; HERPLES SIMPLEX VIRUS 1 MUTANT VIRUS HF10; HERPV VACCINE; IMMUNOGLOBULIN; LIVE VACCINE; PLACEBO; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT VACCINE; RECOMBINANT VIRUS GLYCOPROTEIN B2 VACCINE; RECOMBINANT VIRUS GLYCOPROTEIN D2 VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; VACCINE; VIRUS DNA; VIRUS GLYCOPROTEIN C VACCINE; VIRUS GLYCOPROTEIN D VACCINE; VIRUS GLYCOPROTEIN D2 DNA VACCINE; VIRUS RNA; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GENITAL HERPES; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INCIDENCE; INFECTION PREVENTION; INFECTION RESISTANCE; MONOTHERAPY; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; FEMALE; GENITALIA, FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY, MUCOSAL; MICE;

HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 84875867534     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2012.11.001     Document Type: Article

References (146)

1. Looker K.J., Garnett G.P., Schmid G.P. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008, 86:805-812. [A].
2. Xu F., Sternberg M.R., Kottiri B.J., McQuillan G.M., Lee F.K., Nahmias A.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
3. Johnston C., Koelle D.M., Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest 2011, 121:4600-4609.
4. Szucs T.D., Berger K., Fisman D.N., Harbarth S. The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches. BMC Infect Dis 2001, 1:5.
5. Tao G., Kassler W.J., Rein D.B. Medical care expenditures for genital herpes in the United States. Sex Transm Dis 2000, 27:32-38.
6. Fisman D.N., Hook E.W., Goldie S.J. Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2. Sex Transm Infect 2003, 79:45-52.
7. Kimberlin D.W., Rouse D.J. Clinical practice. Genital herpes. N Engl J Med 2004, 350:1970-1977.
8. Cunningham A.L., Diefenbach R.J., Miranda-Saksena M., Bosnjak L., Kim M., Jones C., et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis 2006, 194(Suppl. 1):S11-S18.
9. Brown Z.A., Selke S., Zeh J., Kopelman J., Maslow A., Ashley R.L., et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997, 337:509-515.
10. Kimberlin D.W., Lin C.Y., Jacobs R.F., Powell D.A., Frenkel L.M., Gruber W.C., et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001, 108:223-229.
11. Brown Z.A., Wald A., Morrow R.A., Selke S., Zeh J., Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003, 289:203-209.
12. Dinh T.H., Dunne E.F., Markowitz L.E., Weinstock H., Berman S. Assessing neonatal herpes reporting in the United States, 2000-2005. Sex Transm Dis 2008, 35:19-21.
13. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 2006, 20:73-83.
14. Celum C.L. The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 2004, 11(Suppl. 1):36A-45A.
15. Mole L., Ripich S., Margolis D., Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997, 176:766-770.
16. Zhu J., Hladik F., Woodward A., Klock A., Peng T., Johnston C., et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009, 15:886-892.
17. Ferreira V.H., Nazli A., Khan G., Mian M.F., Ashkar A.A., Gray-Owen S., et al. Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J Infect Dis 2011, 204:299-308.
18. Xu F., Schillinger J.A., Sternberg M.R., Johnson R.E., Lee F.K., Nahmias A.J., et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 2002, 185:1019-1024.
19. Wald A., Zeh J., Selke S., Warren T., Ryncarz A.J., Ashley R., et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000, 342:844-850.
20. Mark K.E., Wald A., Magaret A.S., Selke S., Olin L., Huang M.L., et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008, 198:1141-1149.
21. Crespi C.M., Cumberland W.G., Wald A., Corey L., Blower S. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect 2007, 83:359-364.
22. Wald A., Corey L., Cone R., Hobson A., Davis G., Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997, 99:1092-1097.
23. Tronstein E., Johnston C., Huang M.L., Selke S., Magaret A., Warren T., et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011, 305:1441-1449.
24. Mertz G.J., Benedetti J., Ashley R., Selke S.A., Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992, 116:197-202.
25. Wald A., Krantz E., Selke S., Lairson E., Morrow R.A., Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006, 194:42-52.
26. Posavad C.M., Remington M., Mueller D.E., Zhao L., Magaret A.S., Wald A., et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 2010, 184:3250-3259.
27. Bochud P.Y., Magaret A.S., Koelle D.M., Aderem A., Wald A. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis 2007, 196:505-509.
28. Zhang S.Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317:1522-1527.
29. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
30. Fish E.N., Banerjee K., Stebbing N. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem Biophys Res Commun 1983, 112:537-546.
31. Leventon-Kriss S., Movshovitz M., Smetana Z., Shewach-Millet M., Doerner T., Gotlieb-Stematsky T. Sensitivity in vitro of herpes simplex virus isolates to human fibroblast interferon. Med Microbiol Immunol 1987, 176:151-159.
32. Nazli A., Yao X.D., Smieja M., Rosenthal K.L., Ashkar A.A., Kaushic C. Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women. Antivir Res 2009, 81:103-112.
33. Gill N., Chenoweth M.J., Verdu E.F., Ashkar A.A. NK cells require type I IFN receptor for antiviral responses during genital HSV-2 infection. Cell Immunol 2011, 269:29-37.
34. Conrady C.D., Halford W.P., Carr D.J. Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection. J Virol 2011, 85:1625-1633.
35. Peng T., Zhu J., Klock A., Phasouk K., Huang M.L., Koelle D.M., et al. Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol 2009, 83:12559-12568.
36. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
37. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001, 2:907-916.
38. Ashkar A.A., Rosenthal K.L. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 2003, 77:10168-10171.
39. Cunningham A.L., Turner R.R., Miller A.C., Para M.F., Merigan T.C. Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest 1985, 75:226-233.
40. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998, 101:1500-1508.
41. Bjorkstrom N.K., Svensson A., Malmberg K.J., Eriksson K., Ljunggren H.G. Characterization of natural killer cell phenotype and function during recurrent human HSV-2 infection. PLoS One 2011, 6:e27664.
42. Donaghy H., Bosnjak L., Harman A.N., Marsden V., Tyring S.K., Meng T.C., et al. Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol 2009, 83:1952-1961.
43. Siegal F.P., Lopez C., Hammer G.S., Brown A.E., Kornfeld S.J., Gold J., et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981, 305:1439-1444.
44. Naraqi S., Jackson G.G., Jonasson O., Yamashiroya H.M. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis 1977, 136:531-540.
45. Meyers J.D., Flournoy N., Thomas E.D. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980, 142:338-346.
46. Morrison L.A. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology 2008, 376:205-210.
47. Iijima N., Linehan M.M., Zamora M., Butkus D., Dunn R., Kehry M.R., et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med 2008, 205:3041-3052.
48. Schiffer J.T., Abu-Raddad L., Mark K.E., Zhu J., Selke S., Koelle D.M., et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A 2010, 107:18973-18978.
49. Mbopi-Keou F.X., Belec L., Dalessio J., Legoff J., Gresenguet G., Mayaud P., et al. Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2. Clin Diagn Lab Immunol 2003, 10:388-393.
50. Cappel R., Sprecher S., De Cuyper F., De Braekeleer J. Clinical efficacy of a herpes simplex subunit vaccine. J Med Virol 1985, 16:137-145.
51. Mertz G.J., Ashley R., Burke R.L., Benedetti J., Critchlow C., Jones C.C., et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990, 161:653-660.
52. Ashley R., Mertz G., Clark H., Schick M., Salter D., Corey L. Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol 1985, 56:475-481.
53. Mester J.C., Highlander S.L., Osmand A.P., Glorioso J.C., Rouse B.T. Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B. J Virol 1990, 64:5277-5283.
54. Straus S.E., Corey L., Burke R.L., Savarese B., Barnum G., Krause P.R., et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994, 343:1460-1463.
55. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV vaccine study group. JAMA 1999, 282:331-340.
56. Langenberg A.G., Corey L., Ashley R.L., Leong W.P., Straus S.E. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV vaccine study group. N Engl J Med 1999, 341:1432-1438.
57. Bernstein D.I., Aoki F.Y., Tyring S.K., Stanberry L.R., St-Pierre C., Shafran S.D., et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005, 40:1271-1281.
58. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347:1652-1661.
59. Immunology Cohen J. Painful failure of promising genital herpes vaccine. Science 2010, 330:304.
60. Straus S.E., Wald A., Kost R.G., McKenzie R., Langenberg A.G., Hohman P., et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997, 176:1129-1134.
61. Koelle D.M., Magaret A., McClurkan C.L., Remington M.L., Warren T., Teofilovici F., et al. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects. Clin Vaccine Immunol 2008, 15:773-782.
62. Wald A., Koelle D.M., Fife K., Warren T., Leclair K., Chicz R.M., et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011, 29:8520-8529.
63. Meignier B., Longnecker R., Mavromara-Nazos P., Sears A.E., Roizman B. Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology 1988, 162:251-254.
64. McLean C.S., Erturk M., Jennings R., Challanain D.N., Minson A.C., Duncan I., et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994, 170:1100-1109.
65. Boursnell M.E., Entwisle C., Blakeley D., Roberts C., Duncan I.A., Chisholm S.E., et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997, 175:16-25.
66. de Bruyn G., Vargas-Cortez M., Warren T., Tyring S.K., Fife K.H., Lalezari J., et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006, 24:914-920.
67. Casanova G., Cancela R., Alonzo L., Benuto R., Magana Mdel C., Hurley D.R., et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002, 70:235-239.
68. Shedlock D.J., Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000, 68:793-806.
69. Cattamanchi A., Posavad C.M., Wald A., Baine Y., Moses J., Higgins T.J., et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 2008, 15:1638-1643.
70. Genocea-Biosciences Genocea initiates a phase 1/2a study with its therapeutic vaccine candidate for herpes simplex virus-2(HSV-2) 2012, http://www.genocea.com/news-events/press-releases/press_release_iscanova_ph1_hsv2_trial_081512.pdf.
71. Brans R., Yao F. Immunization with a dominant-negative recombinant herpes simplex virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol 2010, 10:163.
72. Suter M., Lew A.M., Grob P., Adema G.J., Ackermann M., Shortman K., et al. BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. Proc Natl Acad Sci U S A 1999, 96:12697-12702.
73. Zhang X., Chentoufi A.A., Dasgupta G., Nesburn A.B., Wu M., Zhu X., et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2009, 2:129-143.
74. Armerding D., Mayer P., Scriba M., Hren A., Rossiter H. In-vivo modulation of macrophage functions by herpes simplex virus type 2 in resistant and sensitive inbred mouse strains. Immunobiology 1981, 160:217-227.
75. Scriba M. Persistence of herpes simplex virus (HSV) infection in ganglia and peripheral tissues of guinea pigs. Med Microbiol Immunol 1981, 169:91-96.
76. Scriba M., Tatzber F. Pathogenesis of herpes simplex virus infections in guinea pigs. Infect Immun 1981, 34:655-661.
77. Bourne N., Stanberry L.R., Connelly B.L., Kurawadwala J., Straus S.E., Krause P.R. Quantity of latency-associated transcript produced by herpes simplex virus is not predictive of the frequency of experimental recurrent genital herpes. J Infect Dis 1994, 169:1084-1087.
78. Dudek T., Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006, 344:230-239.
79. Dudek T.E., Torres-Lopez E., Crumpacker C., Knipe D.M. Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis 2011, 203:1434-1441.
80. Krause P.R., Stanberry L.R., Bourne N., Connelly B., Kurawadwala J.F., Patel A., et al. Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med 1995, 181:297-306.
81. Bernstein D.I. Potential for immunotherapy in the treatment of herpesvirus infections. Herpes 2001, 8:8-11.
82. Da Costa X.J., Bourne N., Stanberry L.R., Knipe D.M. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 1997, 232:1-12.
83. Hoshino Y., Dalai S.K., Wang K., Pesnicak L., Lau T.Y., Knipe D.M., et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005, 79:410-418.
84. Hoshino Y., Pesnicak L., Dowdell K.C., Burbelo P.D., Knipe D.M., Straus S.E., et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 2009, 200:1088-1095.
85. Hoshino Y., Pesnicak L., Dowdell K.C., Lacayo J., Dudek T., Knipe D.M., et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 2008, 26:4034-4040.
86. McLean C.S., Ni Challanain D., Duncan I., Boursnell M.E., Jennings R., Inglis S.C. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine 1996, 14:987-992.
87. Meignier B., Longnecker R., Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988, 158:602-614.
88. Prichard M.N., Kaiwar R., Jackman W.T., Quenelle D.C., Collins D.J., Kern E.R., et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005, 23:5424-5431.
89. Spector F.C., Kern E.R., Palmer J., Kaiwar R., Cha T.A., Brown P., et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 1998, 177:1143-1154.
90. Wachsman M., Kulka M., Smith C.C., Aurelian L. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 2001, 19:1879-1890.
91. Bernstein D.I. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine 2000, 18:1351-1358.
92. Bernstein D.I., Earwood J.D., Bravo F.J., Cohen G.H., Eisenberg R.J., Clark J.R., et al. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 2011, 29:2071-2078.
93. Bernstein D.I., Farley N., Bravo F.J., Earwood J., McNeal M., Fairman J., et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 2010, 28:3748-3753.
94. Bourne N., Bravo F.J., Francotte M., Bernstein D.I., Myers M.G., Slaoui M., et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003, 187:542-549.
95. Bourne N., Milligan G.N., Stanberry L.R., Stegall R., Pyles R.B. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 2005, 192:2117-2123.
96. Bourne N., Stanberry L.R., Bernstein D.I., Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996, 173:800-807.
97. Fotouhi F., Soleimanjahi H., Roostaee M.H., Behzadian F. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. FEMS Immunol Med Microbiol 2008, 54:18-26.
98. Heineman T.C., Connelly B.L., Bourne N., Stanberry L.R., Cohen J. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995, 69:8109-8113.
99. McClements W.L., Armstrong M.E., Keys R.D., Liu M.A. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine 1997, 15:857-860.
100. Mester J.C., Twomey T.A., Tepe E.T., Bernstein D.I. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine 1999, 18:875-883.
101. Morello C.S., Levinson M.S., Kraynyak K.A., Spector D.H. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol 2011, 85:3461-3472.
102. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., Nasar F., et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 2006, 80:4447-4457.
103. O'Hagan D., Goldbeck C., Ugozzoli M., Ott G., Burke R.L. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine 1999, 17:2229-2236.
104. Quenelle D.C., Collins D.J., Marciani D.J., Kern E.R. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Vaccine 2006, 24:1515-1522.
105. Scriba M. Recurrent genital herwpes simplex virus (HSV) infection of guinea pigs. Med Microbiol Immunol 1976, 162:201-208.
106. Yim K.C., Carroll C.J., Tuyama A., Cheshenko N., Carlucci M.J., Porter D.D., et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol 2005, 79:14632-14639.
107. McDermott M.R., Smiley J.R., Leslie P., Brais J., Rudzroga H.E., Bienenstock J. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 1984, 51:747-753.
108. Parr M.B., Kepple L., McDermott M.R., Drew M.D., Bozzola J.J., Parr E.L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 1994, 70:369-380.
109. Smith T.J., Morrison L.A., Leib D.A. Pathogenesis of herpes simplex virus type 2 virion host shutoff (vhs) mutants. J Virol 2002, 76:2054-2061.
110. Luo C., Goshima F., Kamakura M., Mutoh Y., Iwata S., Kimura H., et al. Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2. Front Microbiol 2012, 3:158.
111. Lee H.H., Cha S.C., Jang D.J., Lee J.K., Choo D.W., Kim Y.S., et al. Immunization with combined HSV-2 glycoproteins B2: D2 gene DNAs: protection against lethal intravaginal challenges in mice. Virus Genes 2002, 25:179-188.
112. Beutler B., Hoebe K., Du X., Ulevitch R.J. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003, 74:479-485.
113. Gill N., Deacon P.M., Lichty B., Mossman K.L., Ashkar A.A. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J Virol 2006, 80:9943-9950.
114. Ashkar A.A., Yao X.D., Gill N., Sajic D., Patrick A.J., Rosenthal K.L. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 2004, 190:1841-1849.
115. Svensson A., Bellner L., Magnusson M., Eriksson K. Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection. J Reprod Immunol 2007, 74:114-123.
116. Swann J.B., Hayakawa Y., Zerafa N., Sheehan K.C., Scott B., Schreiber R.D., et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007, 178:7540-7549.
117. Martinez J., Huang X., Yang Y. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J Immunol 2008, 180:1592-1597.
118. Milligan G.N., Bernstein D.I. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 1997, 229:259-268.
119. Gill N., Ashkar A.A. Overexpression of interleukin-15 compromises CD4-dependent adaptive immune responses against herpes simplex virus 2. J Virol 2009, 83:918-926.
120. Parr M.B., Parr E.L. Vaginal immunity in the HSV-2 mouse model. Int Rev Immunol 2003, 22:43-63.
121. Parr M.B., Harriman G.R., Parr E.L. Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. Immunology 1998, 95:208-213.
122. Parr E.L., Parr M.B. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J Virol 1997, 71:8109-8115.
123. Russell M.W., Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbe Infect 2002, 4:667-677.
124. Harandi A.M., Svennerholm B., Holmgren J., Eriksson K. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol 2001, 82:845-853.
125. Kuklin N.A., Daheshia M., Chun S., Rouse B.T. Role of mucosal immunity in herpes simplex virus infection. J Immunol 1998, 160:5998-6003.
126. Milligan G.N., Bernstein D.I., Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 1998, 160:6093-6100.
127. McDermott M.R., Goldsmith C.H., Rosenthal K.L., Brais L.J. T lymphocytes in genital lymph nodes protect mice from intravaginal infection with herpes simplex virus type 2. J Infect Dis 1989, 159:460-466.
128. Brabin L. Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. AIDS Patient Care STDS 2002, 16:211-221.
129. Kaushic C., Roth K.L., Anipindi V., Xiu F. Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. J Reprod Immunol 2011.
130. Kaushic C., Ashkar A.A., Reid L.A., Rosenthal K.L. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 2003, 77:4558-4565.
131. Gillgrass A.E., Ashkar A.A., Rosenthal K.L., Kaushic C. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol 2003, 77:9845-9851.
132. Gillgrass A.E., Fernandez S.A., Rosenthal K.L., Kaushic C. Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation. J Virol 2005, 79:3107-3116.
133. Gillgrass A.E., Tang V.A., Towarnicki K.M., Rosenthal K.L., Kaushic C. Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. J Virol 2005, 79:3117-3126.
134. Bhavanam S., Snider D.P., Kaushic C. Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone. Vaccine 2008, 26:6165-6172.
135. Pennock J.W., Stegall R., Bell B., Vargas G., Motamedi M., Milligan G., et al. Estradiol improves genital herpes vaccine efficacy in mice. Vaccine 2009.
136. Roth K.L., Bhavanam S., Jiang H., Gillgrass A., Ho K., Ferreira V.H., et al. Delayed but effective induction of mucosal memory immune responses against genital HSV-2 in the absence of secondary lymphoid organs. Mucosal Immunol 2012.
137. Kwant A., Rosenthal K.L. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 2004, 22:3098-3104.
138. Tengvall S., Josefsson A., Holmgren J., Harandi A.M. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. J Reprod Immunol 2005, 68:53-69.
139. Awasthi S., Lubinski J.M., Shaw C.E., Barrett S.M., Cai M., Wang F., et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 2011, 85:10472-10486.
140. Parr E.L., Parr M.B. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J Virol 1998, 72:5137-5145.
141. Del Campo J., Lindqvist M., Cuello M., Backstrom M., Cabrerra O., Persson J., et al. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 2010, 28:1193-1200.
142. Gallichan W.S., Rosenthal K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998, 177:1155-1161.
143. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001, 166:3451-3457.
144. Milligan G.N., Dudley-McClain K.L., Chu C.F., Young C.G. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Virology 2004, 318:507-515.
145. Parr E.L., Parr M.B. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 1999, 98:639-645.
146. Morrison L.A., Da Costa X.J., Knipe D.M. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 1998, 243:178-187.